Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study (NCT07499440)
HB-1 PTSD
This trial is Currently recruiting
Registration number NCT07499440
Program & service
This trial is being run with the Brain service, and as part of the MAPrc program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Rebecca Ho
Key inclusion data
Aged 18-65; Experiencing symptoms of PTSD; Clinically stable on current medication and/or therapy regimen for at least 2 months No severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to: severe uncontrolled hypertension, hypotension.More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.